Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B
Caleb P Skipper, Mucunguzi Atukunda, Anna Stadelman, Nicole W Engen, Ananta S Bangdiwala, Katherine H Hullsiek, Mahsa Abassi, Joshua Rhein, Melanie R Nicol, Eva Laker, Darlisha A Williams, Raphael Mannino, Theresa Matkovits, David B Meya, David R Boulware, Caleb P Skipper, Mucunguzi Atukunda, Anna Stadelman, Nicole W Engen, Ananta S Bangdiwala, Katherine H Hullsiek, Mahsa Abassi, Joshua Rhein, Melanie R Nicol, Eva Laker, Darlisha A Williams, Raphael Mannino, Theresa Matkovits, David B Meya, David R Boulware
Abstract
Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug delivery into macrophages, where intracellular fungi reside. We conducted a phase I, ascending-dose trial of cAMB administered at 1.0 g, 1.5 g, or 2.0 g per day in 4 to 6 divided doses among HIV-positive survivors of cryptococcosis (n = 9 per cohort). We assessed the tolerability of cAMB and the adverse events (AEs) associated with cAMB treatment over 3 days. A second trial (n = 9) assessed the tolerability of 1.5 g/day given for 7 days. In the single-ascending-dose study, all subjects received their full daily dose without vomiting (100% tolerability). The cohort receiving 1.0 g had 4 transient clinical AEs in 2 subjects within 48 h and 8 laboratory AEs (n = 6 grade 2, n = 2 grade 1). The cohort receiving 1.5 g had 7 clinical AEs in 1 subject attributed to acute gastroenteritis (n = 4 grade 2) and 5 laboratory AEs (n = 1 grade 2). The cohort receiving 2.0 g had 20 clinical AEs among 5 subjects within 48 h (n = 3 grade 2) and 11 laboratory AEs (n = 2 grade 2, n = 1 grade 3). From a qualitative survey, 26 of 27 subjects (96%) preferred their experience with oral cAMB over their prior experience with intravenous (i.v.) AMB. The second, multiple-dose cohort received 1.5 g/day for 1 week, with 98.4% (248/252) of the doses being taken. Overall, 5 clinical AEs (n = 5 grade 1) and 6 laboratory AEs (n = 6 grade 1) occurred without kidney toxicity. Oral cAMB was well tolerated when given in 4 to 6 divided daily doses without the toxicities commonly seen with i.v. AMB. (This study has been registered at ClinicalTrials.gov under registration no. NCT04031833.).
Keywords: Cryptococcus; HIV; amphotericin B; antifungal agents; cryptococcal meningitis; human immunodeficiency virus; pharmacokinetics.
Copyright © 2020 Skipper et al.
Figures
References
- Halde C, Newcomer VD, Wright ET, Sternberg TH. 1957. An evaluation of amphotericin B in vitro and in vivo in mice against Coccidioides immitis and Candida albicans, and preliminary observations concerning the administration of amphotericin B to man. J Invest Dermatol 28:217–231. doi:10.1038/jid.1957.26.
- Lu R, Hollingsworth C, Qiu J, Wang A, Hughes E, Xin X, Konrath KM, Elsegeiny W, Park YD, Atakulu L, Craft JC, Tramont EC, Mannino R, Williamson PR. 2019. Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis. mBio 10:e00724-19. doi:10.1128/mBio.00724-19.
- Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G, COAT Trial Team. 2014. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 370:2487–2498. doi:10.1056/NEJMoa1312884.
- Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, Perlin DS. 2002. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 46:2704–2707. doi:10.1128/aac.46.8.2704-2707.2002.
- Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46:828–833. doi:10.1128/AAC.46.3.828-833.2002.
- Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, Kiggundu R, Pastick KA, Ssebambulidde K, Akampurira A, Williams DA, Bangdiwala AS, Abassi M, Musubire AK, Nicol MR, Muzoora C, Meya DB, Boulware DR, ASTRO-CM Team. 2019. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis 19:843–851. doi:10.1016/S1473-3099(19)30127-6.
- U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. 2017. Common terminology criteria for adverse events (CTCAE) v5.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD.
- U.S. Department of Health and Human Services National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. 2017. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD.
Source: PubMed